atrophy/seizures

Kiungo kimehifadhiwa kwenye clipboard

Chagua aina ya aina

13 matokeo

Method for reducing neuronal degeneration associated with seizure

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

BACKGROUND OF THE INVENTION Morphological changes occur in the adult vertebrate brain both during normal learning and in various neuropathologies such as epilepsy and Alzheimer's disease (Refs. 1-3). These changes include neurodegeneration and more subtle remodeling of the cellular architecture, and

Unified probabilistic framework for predicting and detecting seizure onsets in the brain and multitherapeutic device

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

BACKGROUND OF THE INVENTION The present invention is in the field of medical devices to treat neurological disorders of the brain. More specifically, the invention is directed to a method and a partially or fully implanted apparatus for predicting and detecting epileptic seizure onsets within a

Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to novel tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidine compounds that are antagonists of alpha V (.alpha.v) integrins, for example .alpha..sub.v.beta..sub.3 and .alpha..sub.v.beta..sub.5 integrins, their

8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/NMDA receptor

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

FIELD OF THE INVENTION The present invention is in the field of medicinal chemistry. In particular, the present invention relates to substituted and unsubstituted 8-aza, 6-aza, and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones as well as N-oxides thereof and pharmaceutically acceptable salts thereof

Tricyclic dicarbonyl derivatives

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

This is a 371 application of PCT/EP95/01856, filed May 16, 1995. The present invention is concerned with tricyclic dicarbonyl derivatives of the general formulae ##STR2## wherein R.sup.1 and R.sup.2 each independently signify hydrogen, lower alkyl, lower alkoxy, nitro, trifluoromethyl, amino,

Therapeutic use of antibodies directed against repulsive guidance molecule (RGM)

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

This application is the United States national stage of International Application No. PCT/EP01/15289, filed Dec. 21, 2001, which was published under PCT Article 21(2) in English as International Publication No. WO 02/051438, and which claims benefit of European Patent Application No. 00128356.3

Deuterium-enriched alkyl sulfonamides and uses thereof

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

FIELD OF THE INVENTION The present invention generally relates to deuterium-enriched N-acetylamino-(piperazinyl)-butyl)-alkylsulfonamides of formula 1, their pharmaceutically acceptable salts, synthesis and methods of use thereof. These compounds are 5-HT (serotonin) receptor modulators more

Heterocycles as potassium channel modulators

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

BACKGROUND OF THE INVENTION Ion channels are cellular proteins that regulate the flow of ions, including calcium, potassium, sodium and chloride, into and out of cells. These channels are present in all human cells and affect such processes as nerve transmission, muscle contraction and cellular

Heterocycles as potassium channel modulators

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

Heterocycles as potassium channel modulators

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

NMDA NR2B antagonists for treatment

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

FIELD OF THE INVENTION This invention relates to the treatment of neurological disorders. This invention also relates to the treatment of depression. More particularly, this invention relates to treatment of hearing loss, vision loss, neurodegeneration caused by epileptic seizures, neurotoxin

NMDA NR2B antagonists for treatment

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

Use of RGM and its modulators

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

SEQUENCE LISTING A sequence listing in accordance with 37 C.F.R. .sctn..sctn.1.821-1.825 is attached to the present invention and contained in a file named "8085USC2.txt" (28 Kb, created on Jun. 4, 2012) and is herein fully incorporated by reference. The present invention relates to the use of a

Jiunge na ukurasa
wetu wa facebook

Herbal & Natural Medicine

Hifadhidata kamili ya mimea ya dawa inayoungwa mkono na sayansi

Inafanya kazi katika lugha 55
Uponyaji wa mitishamba unaungwa mkono na sayansi
Kutambua mimea kwa picha
Ramani ya GPS inayoshirikiana
Soma machapisho ya kisayansi yanayohusiana na utafutaji wako
Tafuta mimea ya dawa na athari zao
Panga maslahi yako na fanya tarehe ya utafiti wa habari, majaribio ya kliniki na ruhusu

Andika dalili au ugonjwa na usome juu ya mimea ambayo inaweza kusaidia, chapa mimea na uone magonjwa na dalili ambazo hutumiwa dhidi yake.
* Habari zote zinategemea utafiti wa kisayansi uliochapishwa